questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-26 de cytochromes P450
Famille-26 de cytochromes P450 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Cytochrome P450
Tests génétiques
Cytochrome P450
Métabolites
Troubles hormonaux
Symptômes cliniques
Imagerie médicale
Cytochrome P450
Antécédents médicaux
Traitement médicamenteux
Symptômes
5
Troubles métaboliques
Déséquilibres hormonaux
Douleur
Déséquilibres hormonaux
Éruptions cutanées
Déséquilibres métaboliques
Troubles de l'humeur
Déséquilibres hormonaux
Fertilité
Niveaux hormonaux
Prévention
5
Prévention
Alimentation saine
Tests génétiques
Prévention
Médicaments
Cytochrome P450
Habitudes de vie
Cytochrome P450
Traitements
5
Thérapies hormonales
Ajustements médicamenteux
Alimentation équilibrée
Métabolisme hormonal
Médicaments
Déséquilibres hormonaux
Thérapie génique
Cytochrome P450
Traitements personnalisés
Cytochrome P450
Complications
5
Complications
Troubles métaboliques
Maladies chroniques
Diabète
Qualité de vie
Complications
Réversibilité
Complications
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Âge
Changements hormonaux
Mode de vie
Dysfonctionnement
Facteurs environnementaux
Cytochrome P450
Maladies préexistantes
Cytochrome P450
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Famille-26 de cytochromes P450 : Questions médicales les plus fréquentes",
"headline": "Famille-26 de cytochromes P450 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Famille-26 de cytochromes P450 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-04",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 enzyme system",
"url": "https://questionsmedicales.fr/mesh/D003577",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 enzyme system",
"code": {
"@type": "MedicalCode",
"code": "D003577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Retinoic acid 4-hydroxylase",
"alternateName": "Retinoic Acid 4-Hydroxylase",
"url": "https://questionsmedicales.fr/mesh/D000072516",
"about": {
"@type": "MedicalCondition",
"name": "Retinoic acid 4-hydroxylase",
"code": {
"@type": "MedicalCode",
"code": "D000072516",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.498.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450",
"alternateName": "Cytochrome P450 Family 26",
"code": {
"@type": "MedicalCode",
"code": "D000072500",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David R Nelson",
"url": "https://questionsmedicales.fr/author/David%20R%20Nelson",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA."
}
},
{
"@type": "Person",
"name": "F Peter Guengerich",
"url": "https://questionsmedicales.fr/author/F%20Peter%20Guengerich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu."
}
},
{
"@type": "Person",
"name": "Donghak Kim",
"url": "https://questionsmedicales.fr/author/Donghak%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
},
{
"@type": "Person",
"name": "Emily E Scott",
"url": "https://questionsmedicales.fr/author/Emily%20E%20Scott",
"affiliation": {
"@type": "Organization",
"name": "Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu."
}
},
{
"@type": "Person",
"name": "Vitchan Kim",
"url": "https://questionsmedicales.fr/author/Vitchan%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Depression circuit adaptation in post-stroke depression.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37201899",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jad.2023.05.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dissecting the depressed mood criterion in adult depression: The heterogeneity of mood disturbances in major depressive episodes.",
"datePublished": "2022-11-28",
"url": "https://questionsmedicales.fr/article/36455714",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jad.2022.11.047"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rethinking treatment-resistant depression to quasi-tenacious depression.",
"datePublished": "2023-01-12",
"url": "https://questionsmedicales.fr/article/36632817",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1192/j.eurpsy.2022.2353"
}
},
{
"@type": "ScholarlyArticle",
"name": "Viewpoint: Difficult-to-treat depression versus treatment-resistant depression: A new integrative perspective for managing depression.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37680180",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1192/j.eurpsy.2023.2448"
}
},
{
"@type": "ScholarlyArticle",
"name": "Innate depression.",
"datePublished": "2022-08-23",
"url": "https://questionsmedicales.fr/article/35998233",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/scisignal.ade4885"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-26 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072500"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Famille-26 de cytochromes P450 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Famille-26 de cytochromes P450",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Famille-26 de cytochromes P450",
"description": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?\nQuels tests sont utilisés pour évaluer l'activité des CYP26 ?\nLes symptômes cliniques aident-ils au diagnostic ?\nPeut-on utiliser l'imagerie pour le diagnostic ?\nLes antécédents médicaux sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Depression#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Famille-26 de cytochromes P450",
"description": "Quels sont les symptômes d'une anomalie des CYP26 ?\nLes anomalies des CYP26 causent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes troubles de l'humeur sont-ils liés aux CYP26 ?\nLes anomalies des CYP26 affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Depression#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Famille-26 de cytochromes P450",
"description": "Comment prévenir les dysfonctionnements des CYP26 ?\nLes tests génétiques peuvent-ils prévenir des problèmes ?\nL'évitement de certains médicaments est-il conseillé ?\nLe suivi médical régulier est-il important ?\nLes habitudes de vie influencent-elles la santé des CYP26 ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Depression#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Famille-26 de cytochromes P450",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?\nLes modifications alimentaires aident-elles ?\nDes médicaments spécifiques sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Depression#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Famille-26 de cytochromes P450",
"description": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?\nLes anomalies des CYP26 peuvent-elles causer des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Depression#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Famille-26 de cytochromes P450",
"description": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?\nL'âge influence-t-il le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLes maladies préexistantes augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Depression#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des CYP26 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages de métabolites spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les symptômes cliniques aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des troubles hormonaux peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer les CYP26."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux sont-ils importants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de traitement médicamenteux peuvent influencer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une anomalie des CYP26 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes incluent des troubles métaboliques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs liées à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison de déséquilibres métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur sont-ils liés aux CYP26 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de l'humeur peuvent être liés à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 affectent-elles la fertilité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent affecter la fertilité en perturbant les niveaux hormonaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements des CYP26 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un suivi médical régulier peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des problèmes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques avant l'apparition des symptômes."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments est-il conseillé ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les médicaments connus pour interférer avec les CYP26 peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles la santé des CYP26 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines peuvent améliorer la fonction des CYP26."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies hormonales et des ajustements médicamenteux."
}
},
{
"@type": "Question",
"name": "Les modifications alimentaires aident-elles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut soutenir le métabolisme hormonal."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments ciblant les déséquilibres hormonaux peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est encore en recherche pour traiter les anomalies des CYP26."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 peuvent-elles causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent augmenter le risque de cancers hormonodépendants."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux et l'exposition à certains médicaments."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de changements hormonaux."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils importants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut affecter les CYP26."
}
},
{
"@type": "Question",
"name": "Les maladies préexistantes augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies peuvent prédisposer à des anomalies des CYP26."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 29/03/2025
Contenu vérifié selon les dernières recommandations médicales
10 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA.
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu.
Publications dans "Famille-26 de cytochromes P450" :
4 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
3 publications dans cette catégorie
Affiliations :
Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu.
Publications dans "Famille-26 de cytochromes P450" :
3 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
College of Plant Protection, Hunan Agricultural University, Changsha 410125, P. R. China.
State Key Laboratory of Vegetable Biobreeding, Department of Plant Protection, Institute of Vegetables and Flowers, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Manchester Institute of Biotechnology and Department of Chemical Engineering and Analytical Science, the University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Manchester Institute of Biotechnology and Department of Chemical Engineering and Analytical Science, the University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA 02543.
Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, SA2 8PP Wales, United Kingdom.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA 02543.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, USA.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Huma Toxicology, NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Huma Toxicology, NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Huma Toxicology, NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Microbiology, Faculty of Science, Agriculture and Engineering, University of Zululand, KwaDlangezwa 3886, South Africa.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Food Chemistry Section, Division of Hygienic Chemistry, Osaka Institute of Public Health, Higashinari-ku, Osaka 537-0025, Japan.
Publications dans "Famille-26 de cytochromes P450" :
Lesion locations of post-stroke depression (PSD) mapped to a depression circuit which centered by the left dorsolateral prefrontal cortex (DLPFC). However, it remains unknown whether the compensatory ...
Rs-fMRI data were collected from 82 non-depressed stroke patients (Stroke), 39 PSD patients and 74 healthy controls (HC). We tested the existence of depression circuit, examined PSD-related alteration...
We found that: 1) the left DLPFC showed significantly stronger connectivity to lesions of PSD than Stroke group; 2) in comparison to both Stroke and HC groups, PSD exhibited increased connectivity wit...
Longitudinal studies are required to explore the alterations of depression circuit in PSD as the disease progress....
PSD underwent specific alterations in depression circuit, which may help to establish objective imaging markers for early diagnosis and interventions of the disease....
Mood disturbances have historically remained a core criterion in diagnosing major depressive episode. DSMs have illustrated this criterion with depressed, hopeless, discouraged, cheerless, and irritab...
The current study used a nationally representative sample of U.S. adults with unipolar major depressive disorder to study the association between specific forms of mood disturbances to depression seve...
Cheerless and hopeless mood were associated with depression severity. Hopeless and irritable mood were associated with depression chronicity. Different forms of mood disturbance showed differential re...
The relations between different forms of mood disturbances and various aspects of depression are nuanced. Theoretically, these relations highlight the potential utility in acknowledging the complexity...
With almost one-third of patients with major depression not adequately responsive to treatments, the management of treatment-resistant depression (TRD) has continued to be challenging. Recently, an es...
In the STAR*D study, the efficacy of treatments for major depression was examined. It was found that, while many responded to the initial antidepressant treatment, only 30% of participants achieved co...
Restoring AHI1 in macrophages may improve antiviral immunity in patients with depression....
Depressive disorders encompass a spectrum of diagnoses and are more common in women and transgender individuals. Diagnosis involves thorough history-taking and exclusion of underlying medical disorder...
To review and summarize the literature published between 1 January 2020 and 30 June 2022, on the prevalence, risk factors and impact of depression in transplant population....
Depression is common in transplantation candidates and recipients, with a prevalence up to 85.8% in kidney recipients. Multiple studies have indicated after transplantation depression correlates with ...
Depression is a common finding in transplant population. More research is needed to understand the biological substrate and risk factors and to develop effective treatment interventions....
The goal of this study was to explore the coping strategies of depression sufferers that have worked for them based on the study of an online depression community....
We conducted a thematic narrative analysis of 120 stories posted by the members in the largest online depression community in China. MaxQDA version 18 was used to code the data, and the analytic appro...
The study found that the coping strategies mainly include self-reconciliation (e.g., perceiving/accepting feelings, accepting the present self, and holding hope for the future), actions (recreational ...
The findings revealed the coping strategies that were helpful and examined how they functioned for the affected members, which make up for the lack of attention to the individual experiences of depres...
Evidence-based treatments for adult depression include psychotherapy and pharmacotherapy, yet little is known about how baseline depression severity moderates treatment outcome....
We aimed to compare the effects of psychotherapy and pharmacotherapy for adult depression and to examine the association between baseline depression severity and treatment outcome, converting multiple...
We conducted systematic searches in bibliographical databases up to September 2022 to identify randomized controlled trials (RCTs) in which psychotherapy was compared with pharmacotherapy in the treat...
We identified 65 RCTs including 7250 participants for the meta-analyses and 56 RCTs including 5548 participants for the meta-regression. We found no significant difference between psychotherapy and ph...
Limitations included the low quality of the included studies, and the omission of long-term effects and within-study variability....
We found no indication for a moderation effect of baseline depression severity on the relative effects of psychotherapy and pharmacotherapy. Thus, other factors such as availability and patients' pref...
Depression is a leading cause of disability, affecting approximately 300 million people globally [...]....